News

Public · Published

Truist Securities maintains Madrigal Pharmaceuticals at Buy, raises price target to $743 from $709

Truist Securities kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $743 from $709, a 4.8% increase. The new target implies 87.5% upside from the November 3 closing price of $396.32.

Published:

Updated:

What happened

Truist Securities kept its Buy rating on Madrigal Pharmaceuticals and raised its price target to $743 from $709, a 4.8% increase. The new target implies 87.5% upside from the November 3 closing price of $396.32.

Confirmed

Global impact / market context

The higher target signals that Truist sees more potential share-price appreciation while keeping its positive rating. If investors respond by buying shares, Madrigal’s stock could gain support; however, an analyst target is an estimate, not a guaranteed outcome or a company forecast.

Analyst inference

The update changes Truist’s valuation view, not the company’s reported business results. The implied 87.5% upside compares its target with the November 3 close, so it reflects that reference price and does not establish how the shares have traded since then.

Analyst inference

What to watch

  1. Watch for Madrigal’s future company updates, which could provide evidence that supports or challenges the expectations behind Truist’s higher target. Analyst inference
  2. Check whether other analysts change their ratings or targets; the article reports only Truist’s decision and provides no broader analyst consensus. Analyst inference
  3. Compare the share price with the $743 target over time, remembering that the target is an analyst estimate rather than a promised return. Analyst inference

Evidence

  • Original source link unavailable